Problems of Radiation Medicine and Radiobiology

T. F. Liubarets

Bogomolets National Medical University, Taras Shevchenko Blvd, 13, Kyiv, 01024, Ukraine

TR53 AND IONIZING RADIATION: THE ROLE IN THE PATHOGENESIS AND PROGNOSIS OF THE COURSE OF ACUTE MYELOID LEUKEMIA (literature review)

The review presents literature data on the role of the ТР53 gene and ionizing radiation (IR) in the pathogenesis of acute myeloid leukemia (AML).The violation of ТР53 functioning as a promoter of AML induction under the influence of negative external factors (IR, chemotherapeutic agents) was analyzed. New directions of AML stratification are presented, which will allow to optimize the future therapy and extend the life expectancy of this category of patients.
Key words: acute myeloid leukemia, treatment options, ТР53, ionizing radiation.

Problems of Radiation Medicine and Radiobiology.
2024;29:67-78. doi: 10.33145/2304-8336-2024-29-67-78

full text

1. Fedorenko ZP, Hulak LO, Mykhailovych YuY, Gorokh YeL, Ryzhov AYu, Sumkina OV, Kutsenko LB. Cancer in Ukraine, 2019-2020. Morbidity, mortality, performance indicators of the oncology service [Internet]. Bulletin of the National Cancer Registry of Ukraine. 2021. No. 22. Available from:
http://ncru.inf.ua/publications/BULL_22/index.htm. Application date:03/05/2024.  

2. Vakiti A, Mewawalla P. Acute myeloid leukemia [Internet]. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 Aug 8. Bookshelf ID: NBK507875.  

3. Klokov D, Applegate K, Badie Ch, Brede DA, Dekkers F, Karabulutoglu M, et al. International expert group collaboration for developing an adverse outcome pathway for radiation induced leukemia. Int J Rad Biol. 2022;98(12):1802-15.
https//doi.org/10.1080/09553002.2022.2117873  

4. Folley JH, Borges W, Yamawaki T. Incidence of leukemia in survivors of the atomic bomb in Hiroshima and Nagasaki, Japan. Am J Med. 1952;13(3):311-21.
https//doi.org/10.1016/0002-9343(52)90285-4  

5. Hunter N, Haylock R. Radiation risks of lymphoma and multiple myeloma incidence in the updated NRRW-3 cohort in the UK: 1955-2011. J Radiol Prot. 2022;42(1).
https//doi.org/10.1088/1361-6498/abee96  

6. Hsu W-L, Preston DL, Soda M, Sugiyama H, Funamoto S, Kodama K, et al. The incidence of leukaemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. Radiat Res. 2013;179(3):361-82.
https//doi.org/10.1667/RR2892.1  

7. Laurier D, Richardson DB, Cardis E, Daniels RD, Gillies M, O'Hagan J, et al. The International Nuclear Workers Study (INWORKS): A Collaborative Epidemiological Study to Improve Knowledge About Health Effects of Protracted Low-Dose Exposure. Radiat Prot Dosimetry. 2017;173(1-3):21-5.
https//doi.org/10.1093/rpd/ncw314  

8. Haylock RGE, Gillies M, Hunter N, Zhang W, Phillipson M. Cancer mortality and incidence following external occupational radiation exposure: an update of the 3rd analysis of the UK national registry for radiation workers. Br J Cancer. 2018;119(5):631-37.
https//doi.org/10.1038/s41416-018-0184-9  

9. Linet MS, Little MP, Kitahara CM, Cahoon EK, Doody MM, Simon SL, et al. Occupational radiation and haematopoietic malignancy mortality in the retrospective cohort study of US radiologic technologists, 1983-2012. Occup Environ Med. 2020;77(12):822-31.
https//doi.org/10.1136/oemed-2019-106346  

10. Bazyka D, Prysyazhnyuk A, Gudzenko N, Dyagil I, Belyi D, Chumak V, Buzunov V. Epidemiology of late health effects in Ukrainian Chornobyl cleanup workers. Health Phys. 2018;115(1):161-69.
https//doi.org/10.1097/HP.0000000000000868  

11. Gale RP. Radiation and leukaemia: Which leukaemias and what doses? Blood Rev. 2023;58:101017.
https//doi.org/10.1016/j.blre.2022.101017  

12. Bosch de Basea Gomez M, Thierry-Chef I, Harbron R, Hauptmann M, Byrnes G, Bernier MO, et al. Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults. Nat Med. 2023;29(12):3111-9.
https//doi.org/10.1038/s41591-023-02620-0  

13. Little MP, Wakeford R, Borrego D, French B, Zablotska LB, Adams MJ, et al. Leukaemia and myeloid malignancy among people exposed to low doses (<100 mSv) of ionising radiation during childhood: a pooled analysis of nine historical cohort studies. Lancet Haematol. 2018 Aug;5(8):e346-e358.
https//doi.org/10.1016/S2352-3026(18)30092-9  

14. Leuraud K, Richardson DB, Cardis E, Daniels RD, Gillies M, O'Hagan JA, et al. Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study. Lancet Haematol. 2015;2(7):276-81.
https//doi.org/10.1016/S2352-3026(15)00094-0  

15. Burocziova M, Danek P, Oravetzova A, Chalupova Z, Alberich-Jorda M, Macurek L. Ppm1d truncating mutations promote the development of genotoxic stress-induced AML. Leukemia. 2023;37(11):2209-20.
https//doi.org/10.1038/s41375-023-02030-8  

16. Khranovska NM, Inomistova MV, Svergun NM, Skachkova OV, Klymniuk GI. [The role of changes in regulation of the p53/MDM2 pathway in the progression of neuroblastoma]. Clin. Oncology. 2014;4(16):18-21. Ukrainian.  

17. Muller PAJ, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304-17.
https//doi.org/10.1016/j.ccr.2014.01.021  

18. Zahid MF, Parnes A, Savani BN, Litzow MR, Hashmi SK. Therapy-related myeloid neoplasms - what have we learned so far? World J Stem Cells. 2016;8(8):231-42.
https//doi.org/10.4252/wjsc.v8.i8.231  

19. Haines E, Nishida Y, Carr MI, Montoya RH, Ostermann LB, Zhang W, et al. DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia. Sci Rep. 2021;11(1):12148.
https//doi.org/10.1038/s41598-021-90500-3  

20. Kayser S, Levis MJ. The clinical impact of the molecular landscape of acute myeloid leukemia Haematologica. 2023;108(2):308-20.
https//doi.org/10.3324/haematol.2022.280801  

21. Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377.
https//doi.org/10.1182/blood.2022016867  

22. Standard of Medical Care "Acute Myeloid Leukemia", registration no GC 2023-1873, published on October 30, 2023.